Shaynee Golin
Internal Medicine · Pembroke Pines, FLNPI 1598704447
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $292 and has fallen 92.4% since, to $22 in 2025.
Across 82 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$299
- Novo Nordisk$164
- Boehringer Ingelheim$152
- Lilly USA, LLC$144
- Pfizer$135
- GSK$133
- plus $393 from 13 others
What the payments were for
- Food & beverage$1,419100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $299 |
| Novo Nordisk | 10 | $164 |
| Boehringer Ingelheim | 8 | $152 |
| Lilly USA, LLC | 10 | $144 |
| Pfizer | 7 | $135 |
| GSK | 7 | $133 |
| Amgen(2 entities) | 5 | $80 |
| AbbVie | 3 | $49 |
| Amarin Pharma, Inc. | 2 | $41 |
| Eisai Inc. | 2 | $39 |
| Merck | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Gilead | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Abbott | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $11 |
How this compares
$1,419 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ranolazine ErRanolazine | 12 | $1,342 |
| Omeprazole | 14 | $281 |
| Rosuvastatin Calcium | 34 | $272 |
| Levothyroxine Sodium | 20 | $253 |
| Losartan Potassium | 23 | $237 |
| Buspirone Hcl | 12 | $233 |
| Cyclobenzaprine Hcl | 22 | $208 |
| Escitalopram Oxalate | 20 | $171 |
| Atorvastatin Calcium | 34 | $171 |
| Metformin Hcl | 16 | $132 |
| Lisinopril | 17 | $108 |
| Tamsulosin Hcl | 12 | $105 |
| Simvastatin | 13 | $92 |
| Amlodipine Besylate | 18 | $88 |
| Pantoprazole Sodium | 15 | $75 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Pembroke Pines
- Manuel GonzalezPembroke Pines$37K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.